The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
 
Vicky Makker
Consulting or Advisory Role - Eisai
 
Antonio Casado Herraez
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Carol Aghajanian
Consulting or Advisory Role - Clovis Oncology; Clovis Oncology; Clovis Oncology; Immunogen; Mateon Therapeutics; Mateon Therapeutics; Tesaro; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)
 
Keiichi Fujiwara
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Richard T. Penson
Honoraria - Abbvie; Amgen; AstraZeneca; Baxalta; Clovis Oncology; Eisai; Genentech; Merck; Mersana; Sutter Medical Group; Tesaro; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Baxalta; Care4ward; Clovis Oncology; Eisai; Genentech; Merck; Mersana; Sutter Medical Group; Tesaro; Vascular Biogenics
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Cerulean Pharma (Inst); Eisai (Inst); Genentech (Inst); Regeneron (Inst); Sanofi (Inst); Tesaro (Inst); Vascular Biogenics (Inst)
Patents, Royalties, Other Intellectual Property - Blackwell Publishing; BMJ; UpToDate
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Genentech; Tesaro; Vascular Biogenics
Other Relationship - Abbvie
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai
 
Matthew Guo
Employment - Eisai
Stock and Other Ownership Interests - Amgen; Puma Biotechnology
 
Lea Dutta
Employment - Eisai
 
Robert Orlowski
Employment - Merck
Stock and Other Ownership Interests - Bluebird Bio; Celgene; Kite, a Gilead company; Merck; Nektar; OncoSec
 
Alan Smith
Employment - Eisai
 
David S. Miller
Consulting or Advisory Role - Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Immunogen (Inst); Janssen (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Pfizer (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)